Clinical trial Recruiting at 5 sites Observational Ages 18 and up

Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease

Official title: Real-World Outcomes of Drug-Coated Balloon Angioplasty in Coronary Artery Disease: A Multicenter Ambispective Cohort Study

Run by Hospital Arnau de Vilanova · NCT07875088 · Data updated 2026-11-12

This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2000 (estimated)
SponsorHospital Arnau de Vilanova
Academic / other
Locations5 sites (Mexico City, Mexico City and 4 other locations)
StatusRecruiting
StartedOctober 16, 2026
Main results expectedNovember 2029
Study endsNovember 2030
Registry record updatedOctober 20, 2026
Trial IDNCT07875088 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older undergoing PCI at participating centers with at least one coronary DCB planned or used during the index procedure.

Probably not a fit

Patients for whom a DCB strategy is never planned or used, or whose data are incomplete, may not derive benefit from the findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The RW-DCB is an investigator-led, multicenter observational registry collecting real-world data on the use of drug-coated balloons during percutaneous coronary intervention. It includes consecutive adults where a DCB strategy is planned or attempted, regardless of presentation or lesion type, and regardless of whether the procedure is completed as planned. Data will capture the full intended DCB strategy, including cases where delivery fails, bailouts occur, or strategy changes to another device or therapy are made. Information is collected retrospectively for procedures from 2022 onward and prospectively at each site, using a pseudonymized patient identifier to link procedures, lesions, devices, and follow-up. The study aims to describe the practicality and limitations of DCB use in an all-comer population, including planned hybrid treatments and bailout scenarios.

Why it matters

Potential benefit: If successful, the study could clarify how often DCB strategies are feasible in real-world practice and guide improvements in patient selection and procedural planning.

How similar studies have gone: Previous real-world registries have shown mixed outcomes with DCBs across varied populations; this study adds breadth by including all-comer cases and bailout scenarios.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or older at the index procedure.
* Percutaneous coronary intervention performed at a participating center during its defined study period, in which at least one coronary drug-coated balloon is selected and introduced into the delivery system with intent to treat an epicardial native coronary lesion or a coronary bypass graft lesion.
* Source documentation sufficient to identify the index procedure date, patient, target vessel, and intended drug-coated balloon strategy.
* All clinical presentations and coronary lesion types are eligible.

Exclusion Criteria:

* No coronary drug-coated balloon introduced into the delivery system.
* Withdrawal of authorization for prospectively collected data, when applicable.

Failure to deliver or inflate the intended drug-coated balloon, crossover to another treatment strategy, and incomplete follow-up are not exclusion criteria.

Where it's running

  • Instituto Nacional de Cardiología Ignacio Chávez
    Mexico City, Mexico City, Mexico
    Recruiting
  • Hospital Universitari Son Espases
    Palma de Mallorca, Illes Baleares, Spain
    Recruiting
  • Hospital Universitari Arnau de Vilanova de Lleida
    Lleida, Lleida, Spain
    Recruiting
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid, Spain
    Recruiting
  • Hospital Universitario de Navarra
    Pamplona, Navarre, Spain
    Recruiting

Study contacts

  • Principal investigator: Kristian Rivera, MD, PhD — Hospital Universitari Arnau de Vilanova de Lleida
  • Study coordinator: Kristian Rivera, MD, PhD
  • Email: psrivera.lleida.ics@gencat.cat
  • Phone: 973705273

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.